LUND, Sweden, April 10, 2019 /PRNewswire/ -- Immunovia today
announced that Prof. Stephen Pereira
and his team at the institute for Liver and Digestive Health,
University College London (UCL) will expand the prospective
collection of blood samples funded by Immunovia and that started
with the PanSYM-1 pilot study.
The pilot PanSYM-1 study at UCL that started in 2017 (PR from
November 2nd, 2017) is scheduled for
readout in 2019 and, following today's news, will now support the
continuation of PanSYM-1 as a prospective validation study.
The continued PanSYM-1 study aims to demonstrate the diagnostic
value of IMMray™ PanCan-d in detecting PDAC (pancreatic ductal
adenocarcinoma) earlier than the current standard.
PanSYM-1 aims to collect 2000 single samples. PanSYM-1 sample
collection will through the UCL collaboration be expanded to
include the active network of rapid diagnostic and assessment
centers (RDACs) throughout the UK.
Additionally, UCL is also one of the UK's major screening
centers for familial/hereditary pancreatic cancer, and thus becomes
the latest member of PanFAM-1, Immunovia's global multi-center
study (ClinicalTrials.gov) of familial/hereditary high risk groups
of pancreatic cancer.
Prof. Stephen Pereira, Professor
of Hepatology and Gastroenterology at UCL Institute for Liver and
Digestive Health commented: "We are delighted to participate in the
PanSYM-1 and PanFAM-1 prospective studies. They form one of the
four work packages in the UCL ADEPTS Study (Accelerated Diagnosis
of neuro Endocrine and Pancreatic TumourS) funded by Pancreatic
Cancer UK. They also support significant elements of the NHS long
term plan set this year by working towards faster detection, in
close collaboration with RDACs and helping to diagnose cancers at a
resectable stage which is one of the major cancer milestones."
PanSYM-1 is designed to assess IMMray™ PanCan-d utility in
identifying high risk patients with non-specific but concerning
symptoms attending secondary care centers and endoscopy /
gastrointestinal units. Interim analysis is planned for early 2020
with final results expected in 2021.
Immunovia's CEO Mats Grahn added:
"UCL's ADEPTS study provides the perfect platform for assessing the
utility of IMMray™ PanCan-d. Professor Pereira is a leading
advocate of the use of new diagnostic methods to improve pancreatic
cancer outcomes and we are excited to expand our successful
collaboration with this prestigious center."
For more information, please
contact:
Julie
Silber
Director of Investor
Relations
Email:
julie.silber@immunovia.com
Tel: +46-7-93-486-277
About Immunovia
Immunovia AB was founded in
2007 by investigators from the Department of Immunotechnology at
Lund University and CREATE Health,
the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood-based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases diagnosis,
prognosis and therapy monitoring.
(Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
About the ADEPTS study
The ADEPTS Study (formally referred to as TRANSBIL: TRANSlational
research in BILiary tract and pancreatic diseases) is a UCL
(London) based early biomarker
study which aims to detect pancreatic cancer in patients at a much
earlier stage. It aims to develop a prospective biobank and an
early diagnostic tool that can differentiate early PDAC (pancreatic
ductal adenocarcinoma), PNETs (pancreatic neuroendocrine tumours)
and high-risk pancreatic lesions from benign disease, by combining
a risk factor / early symptom electronic clinical decision support
tool (e-CDST) with novel panels of blood biomarkers of early
disease. This diagnostic tool may then be used for surveillance of
high-risk populations and triage of patients with non-specific
symptoms concerning for pancreatic cancer.
Source:
https://www.ucl.ac.uk/surgery/research/situ-trials/adepts-study-information
The study has four work packages focused on improving early
symptom identification (WP1), development of a biomarker panel for
PNETS (WP2), prospective blood sample collection from symptomatic
patients (WP3) and stakeholder / health economic analysis
(WP4).
About UCLH and rapid diagnostic centers
RDCs are being piloted in ten areas as part of NHS England's
drive to catch cancer early and speed up diagnosis for people with
cancer.
Each of the centres will operate in a different way to ensure
they meet the needs of their local communities. However, all have
the same purpose – to diagnose cancers early in people who do not
have 'alarm symptoms' for a specific type of cancer.
People with vague, non-specific symptoms, such as unexplained
weight loss, appetite loss or abdominal pain are often referred
multiple times for different tests for different cancers, but these
new centres will help end this cycle.
Rapid diagnostic centres are for patients with so-called 'vague'
symptoms that could indicate cancer. These patients need to access
appropriate tests quickly to improve early diagnosis. UCLH is the
lead center of the RDC initiative.
Source:
https://www.england.nhs.uk/2018/04/new-one-stop-shops-for-cancer-to-speed-up-diagnosis-and-save-lives/
A network of at least 20 "rapid diagnostic centres" will working
by 2020, with further centres rolling out across the country before
2030.
Source: Theresa May, Oct 2018
About NHS England
The National Health Service (NHS) is the publicly funded
national healthcare system for England and one of the four National Health
Services for each constituent country of the United Kingdom. It is the largest single-payer
healthcare system in the world, established in 1948. The NHS
provides the majority of healthcare in England, including primary care, in-patient
care, long term healthcare. The NHS Long Term Plan is a new plan
for the NHS to improve the quality of patient care and health
outcomes. It sets out how the £20.5 billion budget settlement for
the NHS, announced by the Prime Minister in summer 2018, will be
spent over the 5 year period from 2019 to 2024, together with long
term objectives over a 10 year period.
NHS England is an executive
non-departmental public body of the Department of Health and Social
Care. It oversees the budget, planning, delivery and day-to-day
operation of the commissioning side of the NHS in England and holds the contracts for general
practitioners and NHS dentists.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/corrected--immunovia-and-university-college-of-london-sign-agreement-to-expand-validation-studies-of,c2785401
The following files are available for download:
https://mb.cision.com/Main/13121/2785401/1023239.pdf
|
PDF
|